Vavricka John

CIK 00018296301 companyBOSTON, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001829630

Recent Transactions

21 trades

Exercise/Conversion
Atea Pharmaceuticals, Inc.$AVIR
Common Stock
2026-01-31+42,083→ 94,164 total
Award
Atea Pharmaceuticals, Inc.$AVIR
Stock Option (Right to Buy)
2026-01-31+119,520→ 119,520 total
Exercise/Conversion
Atea Pharmaceuticals, Inc.$AVIR
Restricted Stock Units
2026-01-31−8,750→ 0 total
Exercise/Conversion
Atea Pharmaceuticals, Inc.$AVIR
Restricted Stock Units
2026-01-31−33,333→ 0 total
Tax Payment
Atea Pharmaceuticals, Inc.$AVIR
Common Stock
2026-01-31$4.24/sh−11,570→ 82,594 total
Exercise/Conversion
Atea Pharmaceuticals, Inc.$AVIR
Common Stock
2025-01-31+33,333→ 54,848 total
Award
Atea Pharmaceuticals, Inc.$AVIR
Common Stock
2025-01-31+8,750→ 63,598 total
Exercise/Conversion
Atea Pharmaceuticals, Inc.$AVIR
Restricted Stock Units
2025-01-31−33,333→ 33,333 total
Award
Atea Pharmaceuticals, Inc.$AVIR
Restricted Stock Units
2025-01-31+8,750→ 8,750 total
Award
Atea Pharmaceuticals, Inc.$AVIR
Stock Option (Right to Buy)
2025-01-31+132,800→ 132,800 total
Tax Payment
Atea Pharmaceuticals, Inc.$AVIR
Common Stock
2025-01-31$3.06/sh−11,517→ 52,081 total
Sale
Atea Pharmaceuticals, Inc.$AVIR
Common Stock
2024-02-01$3.84/sh−11,819→ 21,515 total
Exercise/Conversion
Atea Pharmaceuticals, Inc.$AVIR
Common Stock
2024-01-31+33,334→ 33,334 total
Award
Atea Pharmaceuticals, Inc.$AVIR
Stock Option (Right to Buy)
2024-01-31+132,800→ 132,800 total
Exercise/Conversion
Atea Pharmaceuticals, Inc.$AVIR
Restricted Stock Units
2024-01-31−33,334→ 66,666 total
Award
Atea Pharmaceuticals, Inc.$AVIR
Restricted Stock Units
2023-01-31+100,000→ 100,000 total
Award
Atea Pharmaceuticals, Inc.$AVIR
Stock Option (Right to Buy)
2023-01-31+140,000→ 140,000 total
Award
Atea Pharmaceuticals, Inc.$AVIR
Stock Option (Right to Buy)
2022-01-31+135,000→ 135,000 total
Award
Atea Pharmaceuticals, Inc.$AVIR
Stock Option (Right to Buy)
2021-01-29+117,300→ 117,300 total
Conversion
Atea Pharmaceuticals, Inc.$AVIR
Common Stock
2020-11-03+82,508→ 82,508 total
Conversion
Atea Pharmaceuticals, Inc.$AVIR
Series B Convertible Preferred Stock
2020-11-03−82,508→ 0 total

Companies

Atea Pharmaceuticals, Inc.
Chief Commercial Officer
$AVIR

Recent Filings

Address

225 FRANKLIN STREET SUITE 2100

BOSTON, MA, 02110

View on SEC.gov